Recent advances in understanding the mechanism of action of bisphosphonates.

doi:10.1016/J.COPH.2006.03.005

Paper

DOI: 10.1016/J.COPH.2006.03.005

Recent advances in understanding the mechanism of action of bisphosphonates.

Published Jun 1, 2006 · F. Coxon, K. Thompson, M. Rogers

Current opinion in pharmacology

Q1 SJR score

257

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Highly Cited

Study Snapshot

Bisphosphonates effectively treat osteoporosis by inhibiting osteoclast-mediated bone resorption, and their mechanism of action may lead to the development of novel inhibitors of bone resorption.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1002/ijc.21977

Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S‐phase arrest, in human myeloma cells

Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis in human myeloma cells, but not S-phase arrest, identifying distinct molecular pathways responsible for antimyeloma effects.

2006·61citations·A. Roelofs et al.·International Journal of Cancer

International Journal of Cancer

DOI: 10.1016/J.BONE.2005.07.023

Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.

Most clinically tested bisphosphonates have similar affinities for human bone, but those with reduced affinity may have lower antiresorptive potency, necessitating higher dosing.

2006·147citations·C. Leu et al.·Bone

Bone

DOI: 10.1016/J.BONE.2005.05.003

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.

Bisphosphonates' binding affinities for hydroxyapatite vary, potentially impacting their uptake, persistence, and reversibility in bone.

2006·818citations·G. H. Nancollas et al.·Bone

Bone

DOI: 10.1359/jbmr.060118

Inhibition of Protein Prenylation by Bisphosphonates Causes Sustained Activation of Rac, Cdc42, and Rho GTPases

N-BPs inhibit bone resorption by preventing prenylation of small GTPases, leading to the accumulation of unprenylated small GTPases and inappropriate activation of downstream signaling pathways.

2006·178citations·J. Dunford et al.·Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

DOI: 10.1124/mol.105.020776

Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of Vesicles after Fluid-Phase Endocytosis

Bisphosphonate drugs enter cells through fluid-phase endocytosis, which is enhanced by calcium ions, and then enter the cytosol through endosomal acidification.

2006·241citations·K. Thompson et al.·Molecular Pharmacology

Molecular Pharmacology

Citations

DOI: 10.3390/ijms251910488

Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives

Genetic factors, such as SIRT1, VEGFA, and CYP2C8, play a role in the development of medication-related osteonecrosis of the jaw, which can be better managed by understanding its complex genetic background.

2024·0citations·Bence Bojtor et al.·International Journal of Molecular Sciences

International Journal of Molecular Sciences

DOI: 10.3389/fcell.2024.1431566

Lysosomal biogenesis and function in osteoclasts: a comprehensive review

Targeting lysosomes in osteoclasts may offer potential therapeutic benefits for treating bone metabolic disorders.

2024·0citations·Junchen Jiang et al.·Frontiers in Cell and Developmental Biology

Frontiers in Cell and Developmental Biology

DOI: 10.21203/rs.3.rs-4237258/v1

Hydroxychloroquine and a low activity bisphosphonate conjugate prevent and reverse ovariectomy-induced bone loss in mice through dual antiresorptive and anabolic effects

The combination of HABP and HCQ could prevent and treat osteoporosis by promoting bone formation and decreasing bone resorption simultaneously.

2024·0citations·Z. Yao et al.·Research Square

Research Square

DOI: 10.1021/acscentsci.3c01414

Discovery of a Potent Antiosteoporotic Drug Molecular Scaffold Derived from Angelica sinensis and Its Bioinspired Total Synthesis

Falcarinphthalide A (1), a promising lead compound from Angelica sinensis, exhibits potent antiosteoporotic activity by inhibiting NF-B and c-Fos signaling-mediated osteoclastogenesis.

2024·5citations·Jian Zou et al.·ACS Central Science

ACS Central Science

DOI: 10.1016/j.ijpharm.2023.123640

Enhancing Osteosarcoma Therapy through Aluminium Hydroxide Nanosheets-Enabled Macrophage Modulation.

Aluminium hydroxide nanosheets combined with zoledronic acid can enhance osteosarcoma therapy by inhibiting cell growth and enhancing macrophage activation.

2023·1citation·Min Cheng et al.·International journal of pharmaceutics

International journal of pharmaceutics